IL6 Signaling in Peripheral Blood T Cells Predicts Clinical Outcome in Breast Cancer
Autor: | James Waisman, Carrie Wang, Diana L. Simons, Xuyang Lu, John H. Yim, Vernon C. Maino, Maria A. Suni, Andrea K. Miyahira, Peter P. Lee, Lei Wang, Frederick M. Dirbas, Andrew Y. Chang |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
CD4-Positive T-Lymphocytes musculoskeletal diseases 0301 basic medicine Cancer Research Adolescent medicine.medical_treatment Breast Neoplasms Article Young Adult 03 medical and health sciences 0302 clinical medicine Breast cancer Immune system Downregulation and upregulation immune system diseases Cancer stem cell Biomarkers Tumor medicine Humans skin and connective tissue diseases Aged Aged 80 and over Interleukin-6 business.industry Cancer Middle Aged medicine.disease biological factors Treatment Outcome 030104 developmental biology Cytokine Oncology Case-Control Studies 030220 oncology & carcinogenesis Immunology Cancer cell Cancer research Female Signal transduction business Signal Transduction |
Zdroj: | Cancer Research. 77:1119-1126 |
ISSN: | 1538-7445 0008-5472 |
Popis: | IL6 is a pleiotropic cytokine with both pro- and anti-inflammatory properties, which acts directly on cancer cells to promote their survival and proliferation. Elevated serum IL6 levels negatively correlate with survival of cancer patients, which is generally attributed to the direct effects of IL6 on cancer cells. How IL6 modulates the host immune response in cancer patients is unclear. Here, we show the IL6 signaling response in peripheral blood T cells is impaired in breast cancer patients and is associated with blunted Th17 differentiation. The mechanism identified involved downregulation of gp130 and IL6Rα in breast cancer patients and was independent of plasma IL6 levels. Importantly, defective IL6 signaling in peripheral blood T cells at diagnosis correlated with worse relapse-free survival. These results indicate that intact IL6 signaling in T cells is important for controlling cancer progression. Furthermore, they highlight a potential for IL6 signaling response in peripheral blood T cells at diagnosis as a predictive biomarker for clinical outcome of breast cancer patients. Cancer Res; 77(5); 1119–26. ©2016 AACR. |
Databáze: | OpenAIRE |
Externí odkaz: |